Funding for this research was provided by:
Ministry of Science and Technology of the People's Republic of China (2012CB837600)
Beijing Municipal Science and Technology Commission, and Beijing Key Laboratory of Pathogen Invasion and Immune Defense (Z171100002217064)
Received: 27 February 2022
Accepted: 2 January 2023
First Online: 17 January 2023
: Human PBMCs were purchased from Shanghai Aoneng Biotechnology Co., Ltd. The use of these samples was approved by the IRB of NIBS. All animal studies were conducted following the National Guidelines for the Housing and Care of Laboratory Animals in China and performed under approved Institutional Animal Care and Use Committee (IACUC) protocols at the National Institute of Biological Sciences, Beijing.
: Not applicable.
: YL, JL, and JS are inventors of a patent application regarding the pH-dependent antibodies. Other authors declare no conflict of interest.